234 related articles for article (PubMed ID: 24072883)
1. Targeting plasminogen activator inhibitor-1 inhibits angiogenesis and tumor growth in a human cancer xenograft model.
Gomes-Giacoia E; Miyake M; Goodison S; Rosser CJ
Mol Cancer Ther; 2013 Dec; 12(12):2697-708. PubMed ID: 24072883
[TBL] [Abstract][Full Text] [Related]
2. Protumorigenic activity of plasminogen activator inhibitor-1 through an antiapoptotic function.
Fang H; Placencio VR; DeClerck YA
J Natl Cancer Inst; 2012 Oct; 104(19):1470-84. PubMed ID: 22984202
[TBL] [Abstract][Full Text] [Related]
3. Effect of pharmacologic plasminogen activator inhibitor-1 inhibition on cell motility and tumor angiogenesis.
Leik CE; Su EJ; Nambi P; Crandall DL; Lawrence DA
J Thromb Haemost; 2006 Dec; 4(12):2710-5. PubMed ID: 17010152
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of plasminogen activator inhibitor-1 is a potential therapeutic strategy in ovarian cancer.
Mashiko S; Kitatani K; Toyoshima M; Ichimura A; Dan T; Usui T; Ishibashi M; Shigeta S; Nagase S; Miyata T; Yaegashi N
Cancer Biol Ther; 2015; 16(2):253-60. PubMed ID: 25587663
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of PAI-1 Limits Tumor Angiogenesis Regardless of Angiogenic Stimuli in Malignant Pleural Mesothelioma.
Takayama Y; Hattori N; Hamada H; Masuda T; Omori K; Akita S; Iwamoto H; Fujitaka K; Kohno N
Cancer Res; 2016 Jun; 76(11):3285-94. PubMed ID: 27197170
[TBL] [Abstract][Full Text] [Related]
6. Plasminogen activator inhibitor-1 inhibits prostate tumor growth through endothelial apoptosis.
Chen SC; Henry DO; Reczek PR; Wong MK
Mol Cancer Ther; 2008 May; 7(5):1227-36. PubMed ID: 18483310
[TBL] [Abstract][Full Text] [Related]
7. PAI-1 leads to G1-phase cell-cycle progression through cyclin D3/cdk4/6 upregulation.
Giacoia EG; Miyake M; Lawton A; Goodison S; Rosser CJ
Mol Cancer Res; 2014 Mar; 12(3):322-34. PubMed ID: 24464915
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological Targeting of Plasminogen Activator Inhibitor-1 Decreases Vascular Smooth Muscle Cell Migration and Neointima Formation.
Ji Y; Weng Z; Fish P; Goyal N; Luo M; Myears SP; Strawn TL; Chandrasekar B; Wu J; Fay WP
Arterioscler Thromb Vasc Biol; 2016 Nov; 36(11):2167-2175. PubMed ID: 27659097
[TBL] [Abstract][Full Text] [Related]
9. Plasminogen Activator Inhibitor-1 in Cancer: Rationale and Insight for Future Therapeutic Testing.
Placencio VR; DeClerck YA
Cancer Res; 2015 Aug; 75(15):2969-74. PubMed ID: 26180080
[TBL] [Abstract][Full Text] [Related]
10. Plasminogen activator inhibitor-1 as regulator of tumor-initiating cell properties in head and neck cancers.
Lee YC; Yu CC; Lan C; Lee CH; Lee HT; Kuo YL; Wang PH; Chang WW
Head Neck; 2016 Apr; 38 Suppl 1():E895-904. PubMed ID: 25974262
[TBL] [Abstract][Full Text] [Related]
11. Plasminogen activator inhibitor-1 (PAI-1) gene transfection inhibits the liver metastasis of pancreatic cancer by preventing angiogenesis.
Inoue M; Sawada T; Uchima Y; Kimura K; Nishihara T; Tanaka H; Yashiro M; Yamada N; Ohira M; Hirakawa K
Oncol Rep; 2005 Dec; 14(6):1445-51. PubMed ID: 16273237
[TBL] [Abstract][Full Text] [Related]
12. SK-216, an inhibitor of plasminogen activator inhibitor-1, limits tumor progression and angiogenesis.
Masuda T; Hattori N; Senoo T; Akita S; Ishikawa N; Fujitaka K; Haruta Y; Murai H; Kohno N
Mol Cancer Ther; 2013 Nov; 12(11):2378-88. PubMed ID: 23990114
[TBL] [Abstract][Full Text] [Related]
13. A novel form of the plasminogen activator inhibitor created by cysteine mutations extends its half-life: relevance to cancer and angiogenesis.
Chorostowska-Wynimko J; Swiercz R; Skrzypczak-Jankun E; Wojtowicz A; Selman SH; Jankun J
Mol Cancer Ther; 2003 Jan; 2(1):19-28. PubMed ID: 12533669
[TBL] [Abstract][Full Text] [Related]
14. PAI-1 is a potential transcriptional silencer that supports bladder cancer cell activity.
Furuya H; Sasaki Y; Chen R; Peres R; Hokutan K; Murakami K; Kim N; Chan OTM; Pagano I; Dyrskjøt L; Jensen JB; Malmstrom PU; Segersten U; Sun Y; Arab A; Goodarzi H; Goodison S; Rosser CJ
Sci Rep; 2022 Jul; 12(1):12186. PubMed ID: 35842542
[TBL] [Abstract][Full Text] [Related]
15. Recombinant PAI-1 inhibits angiogenesis and reduces size of LNCaP prostate cancer xenografts in SCID mice.
Swiercz R; Keck RW; Skrzypczak-Jankun E; Selman SH; Jankun J
Oncol Rep; 2001; 8(3):463-70. PubMed ID: 11295064
[TBL] [Abstract][Full Text] [Related]
16. Pirfenidone inhibits motility of NSCLC cells by interfering with the urokinase system.
Krämer M; Markart P; Drakopanagiotakis F; Mamazhakypov A; Schaefer L; Didiasova M; Wygrecka M
Cell Signal; 2020 Jan; 65():109432. PubMed ID: 31693876
[TBL] [Abstract][Full Text] [Related]
17. Breast cancer and metabolic syndrome linked through the plasminogen activator inhibitor-1 cycle.
Beaulieu LM; Whitley BR; Wiesner TF; Rehault SM; Palmieri D; Elkahloun AG; Church FC
Bioessays; 2007 Oct; 29(10):1029-38. PubMed ID: 17876797
[TBL] [Abstract][Full Text] [Related]
18. Oridonin inhibits tumor growth and metastasis through anti-angiogenesis by blocking the Notch signaling.
Dong Y; Zhang T; Li J; Deng H; Song Y; Zhai D; Peng Y; Lu X; Liu M; Zhao Y; Yi Z
PLoS One; 2014; 9(12):e113830. PubMed ID: 25485753
[TBL] [Abstract][Full Text] [Related]
19. Anti-tumor effects of ONC201 in combination with VEGF-inhibitors significantly impacts colorectal cancer growth and survival in vivo through complementary non-overlapping mechanisms.
Wagner J; Kline CL; Zhou L; Khazak V; El-Deiry WS
J Exp Clin Cancer Res; 2018 Jan; 37(1):11. PubMed ID: 29357916
[TBL] [Abstract][Full Text] [Related]
20. The effect of plasminogen activator inhibitor type 1 on apoptosis.
Schneider DJ; Chen Y; Sobel BE
Thromb Haemost; 2008 Dec; 100(6):1037-40. PubMed ID: 19132227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
